X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES DR. REDDYS LAB ALKEM LABORATORIES/
DR. REDDYS LAB
 
P/E (TTM) x - 29.9 - View Chart
P/BV x 7.3 2.9 249.6% View Chart
Dividend Yield % 0.6 0.9 64.3%  

Financials

 ALKEM LABORATORIES   DR. REDDYS LAB
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
DR. REDDYS LAB
Mar-17
ALKEM LABORATORIES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,5893,397 46.8%   
Low Rs1,2322,560 48.1%   
Sales per share (Unadj.) Rs417.5856.5 48.7%  
Earnings per share (Unadj.) Rs56.378.0 72.2%  
Cash flow per share (Unadj.) Rs64.7139.9 46.3%  
Dividends per share (Unadj.) Rs12.7020.00 63.5%  
Dividend yield (eoy) %0.90.7 134.1%  
Book value per share (Unadj.) Rs292.9739.8 39.6%  
Shares outstanding (eoy) m119.57165.74 72.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.43.5 97.2%   
Avg P/E ratio x25.138.2 65.6%  
P/CF ratio (eoy) x21.821.3 102.4%  
Price / Book Value ratio x4.84.0 119.6%  
Dividend payout %22.625.7 87.9%   
Avg Mkt Cap Rs m168,653493,632 34.2%   
No. of employees `000NA22.7 0.0%   
Total wages/salary Rs m9,17131,068 29.5%   
Avg. sales/employee Rs ThNM6,259.0-  
Avg. wages/employee Rs ThNM1,369.8-  
Avg. net profit/employee Rs ThNM569.7-  
INCOME DATA
Net Sales Rs m49,915141,961 35.2%  
Other income Rs m1,6451,715 95.9%   
Total revenues Rs m51,561143,676 35.9%   
Gross profit Rs m8,48224,722 34.3%  
Depreciation Rs m1,00610,266 9.8%   
Interest Rs m671634 105.8%   
Profit before tax Rs m8,45115,537 54.4%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6062,965 54.2%   
Profit after tax Rs m6,73112,921 52.1%  
Gross profit margin %17.017.4 97.6%  
Effective tax rate %19.019.1 99.6%   
Net profit margin %13.59.1 148.2%  
BALANCE SHEET DATA
Current assets Rs m27,06296,837 27.9%   
Current liabilities Rs m15,32484,199 18.2%   
Net working cap to sales %23.58.9 264.2%  
Current ratio x1.81.2 153.6%  
Inventory Days Days6773 90.7%  
Debtors Days Days4198 42.3%  
Net fixed assets Rs m12,610102,552 12.3%   
Share capital Rs m239829 28.8%   
"Free" reserves Rs m34,490121,792 28.3%   
Net worth Rs m35,027122,621 28.6%   
Long term debt Rs m1,2125,449 22.2%   
Total assets Rs m54,387218,165 24.9%  
Interest coverage x13.625.5 53.3%   
Debt to equity ratio x00 77.8%  
Sales to assets ratio x0.90.7 141.0%   
Return on assets %13.66.2 219.0%  
Return on equity %19.210.5 182.4%  
Return on capital %24.912.9 192.7%  
Exports to sales %12.954.6 23.7%   
Imports to sales %3.19.4 33.0%   
Exports (fob) Rs m6,46177,520 8.3%   
Imports (cif) Rs m1,54013,274 11.6%   
Fx inflow Rs m6,56381,670 8.0%   
Fx outflow Rs m3,01226,355 11.4%   
Net fx Rs m3,55255,315 6.4%   
CASH FLOW
From Operations Rs m7,25921,444 33.8%  
From Investments Rs m1,864-18,404 -10.1%  
From Financial Activity Rs m-9,273-3,692 251.2%  
Net Cashflow Rs m-150-1,144 13.1%  

Share Holding

Indian Promoters % 66.9 25.5 262.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.4 613.0%  
FIIs % 0.0 35.3 -  
ADR/GDR % 0.0 18.5 -  
Free float % 0.0 15.3 -  
Shareholders   68,381 75,885 90.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 21, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS